A-423579 Explained

A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H₃ subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.^{[1] [2]}

Notes and References

1. Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB . In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists . Basic & Clinical Pharmacology & Toxicology . 95 . 3 . 144–52 . September 2004 . 15447739 . 10.1111/j.1742-7843.2004.950307.x . free .
2. Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB . Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy . Inflammation Research . 54 . S27–9 . April 2005 . 15928821 . 10.1007/s00011-004-0412-z . 22094031 .